ET Press release content from Globe Newswire. This press release and prior releases are available at www.aimimmuno.com. Press release content from Globe Newswire. AIM ImmunoTech Inc. (AMEX:AIM) went down by -7.41% from its latest closing price compared to the recent 1-year high of $4.30. AIM IMMUNOTECH INC. : Press releases relating to AIM IMMUNOTECH INC. Investor relations | Deutsche Boerse AG: HXB2 | Deutsche Boerse AG în Politica noastră de confidențialitate și în Politica privind modulele cookie. OCALA, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced developments in its work to develop … OCALA, FL / ACCESSWIRE, Feb 27, 2020 - (ACN Newswire) - AIM ImmunoTech (NYSE American: AIM, or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the Company has joined with ChinaGoAbroad (CGA) to facilitate the entry of AIM… --AIM ImmunoTech Inc. today announced that the active AMP-511 Expanded Access Program has dosed its first COVID-19“ Long Hauler” patient with the drug Ampligen, marking a … The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. “Our objective is to expedite the development of Ampligen as potential prophylaxis or treatment for Covid-19. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus. However, alongside AIM ImmunoTech’s terrific-sounding public service updates being broadcast almost exclusively via press releases out of Florida … Contacts: Crescendo Communications, LLC Phone: 212-671-1021 Email: [email protected] AIM ImmunoTech Inc Phone: 800-778-4042 Press Release reported on 03/22/21 that AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center’s Ongoing Study in Cancer Patients with … This press release and prior releases are available at www.aimimmuno.com. Press Release AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th Published: March 11, 2021 at 7:00 a.m. The AP news staff was not involved in its creation. 12/24/2020 | 08:16am EDT *: *: * DGAP-News: AIM ImmunoTech Inc / Key word(s): Miscellaneous AIM ImmunoTech Inc: AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for … CONTACT: Crescendo Communications, LLC Phone: 212-671-1021 Email: [email protected] AIM ImmunoTech Inc Phone: 800-778-4042 In particular, there was an update on AIM ImmunoTech’s fiscal standing. AIM ImmunoTech Inc Phone: 800-778-4042 OCALA, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a … AIM ImmunoTech Inc. (AMEX:AIM) went down by -0.96% from its latest closing price compared to the recent 1-year high of $4.30. --AIM ImmunoTech Inc. today announced that the Institutional Review Board of Roswell Park Comprehensive Cancer Center has approved a protocol amendment to Roswell Park’ s … AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and … AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo. Press Release AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands Published: Feb. 10, 2021 at 9:15 a.m. AIM ImmunoTech CEO Thomas Equels said: “We greatly appreciate the tremendous efforts of the entire team at CHDR to help us initiate our Phase 1 study of Ampligen as a potential intranasal therapy. Press Releases AIM ImmunoTech 2019-04-23T08:44:59-04:00 PDF Print View All: July 06, 2020: AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi, a Leading Global Pharmaceutical Company, to Test Ampligen as Potential Vaccine Adjuvant for COVID-19 : OCALA, FL / July 6, 2020 / AIM ImmunoTech (NYSE American:AIM… Contacts: Crescendo Communications, LLC Phone: 212-671-1021 Email: [email protected] AIM ImmunoTech Inc Phone: 800-778-4042 OCALA, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a ‘Fireside Chat’ video interview with Ed Woo, Director of Research & Senior Analyst at Ascendiant Capital Markets. Press Release reported on 05/03/21 that AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo 2020 Financial Highlights . The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. ET The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. --AIM ImmunoTech Inc. today announced that it has entered into a sponsorship agreement with the Centre for Human Drug Research for the proposed AMP-COV-100 clinical study on the safety of AIM… The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. As of December 31, 2020, AIM had cash, cash equivalents and marketable securities of … Words such as “may,” “will,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. OCALA, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a 'Fireside Chat' video interview with Ed Woo, Director of [...], 2021-04-27T07:16:08-04:00April 27th, 2021|, OCALA, Fla., April 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability [...], 2021-04-07T09:16:36-04:00April 7th, 2021|, OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM's [...], 2021-03-31T09:16:38-04:00March 31st, 2021|, OCALA, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update.2020 Financial HighlightsAs of December 31, [...], 2021-03-22T08:45:58-04:00March 22nd, 2021|, OCALA, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center (Roswell Park) has approved a protocol amendment [...], 2021-03-11T07:01:34-05:00March 11th, 2021|, OCALA, Fla., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire - AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the Q1 [...], AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo, AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases, AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases, AIM ImmunoTech Reports 2020 Year-End Financial Results, AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center’s Ongoing Study in Cancer Patients with COVID-19, AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th. Vă puteți modifica opțiunile în orice moment, vizitând Controale de confidențialitate. Press release content from Globe Newswire. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. AIM ImmunoTech Inc. December 24, 2020 GMT. Press Release AIM ImmunoTech Reports 2020 Year-End Financial Results Published: March 31, 2021 at 9:15 a.m. Press Release AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy Published: Feb. 16, 2021 at 9:15 a.m. OCALA, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a … This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). AIM ImmunoTech has dosed the first healthy participants in a Phase I clinical study of its Ampligen drug as a potential intranasal prophylaxis or early-stage treatment for Covid-19 and other respiratory viral diseases. Press Releases AIM ImmunoTech 2019-04-23T08:44:59-04:00 PDF Print View All: March 09, 2020: AIM ImmunoTech's Drug Ampligen to Be Tested by Japan's National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19 : OCALA, FL / March 9, 2020 / AIM ImmunoTech (NYSE American:AIM… cu caracter personal, pentru a afișa conținut și reclame personalizate, pentru măsurarea eficienței reclamelor și a conținutului, pentru statistici despre public și pentru dezvoltarea de produse. That same press release included a nice bonus. ET OCALA, Fla., Nov. 13, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided a business update for the third quarter ended September 30, 2020. OCALA, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech … The AP news staff was not involved in its creation. AIM IMMUNOTECH INC. : Press releases relating to AIM IMMUNOTECH INC. Investor relations | Nyse: AIM | Nyse ... (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, reporting no serious adverse events, and paving the way for escalation of the dose … OCALA, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center (Roswell Park) has approved a protocol amendment to Roswell Park’s ongoing Phase 1/2a study evaluating the two-drug combination of AIM’s Ampligen and interferon … AIM ImmunoTech Announces Addition Of Single-Agent Ampligen Arm To Cancer Center's Ongoing Study In Cancer Patients With COVID-19. OCALA, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of … Press Release: AIM ImmunoTech's Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer Press Release 02/24/21 The company’s stock price has collected -4.63% of loss in the last five trading sessions. The AP news staff was not involved in its creation. Skip to main content. AIM ImmunoTech Inc. - 8-K, Current Report: 07.04. Puteți selecta „Administrare setări” pentru a afla mai multe informații și a vă gestiona opțiunile. AIM ImmunoTech Inc. (AMEX:AIM) went down by -3.78% from its latest closing price compared to the recent 1-year high of $7.11. Find the latest press releases from AIM ImmunoTech Inc. Common Stock (AIM) at Nasdaq.com. During the Fireside Chat, Equels discusses recent accomplishments, key upcoming goals and milestones, as well … Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act (PSLRA) of 1995. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus. The company’s stock price has collected -11.06% of loss in the last five trading sessions. OCALA, FL / ACCESSWIRE / September 25, 2019 / AIM ImmunoTech, Inc. (NYSE American:AIM) (the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced the pricing of an underwritten public offering of (i) 1,740,550 shares of common stock together with common stock warrants (the … OCALA, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a ‘Fireside Chat’ video interview with Ed Woo, Director of Research & Senior Analyst at Ascendiant Capital Markets. PRESS RELEASES. This press release and prior releases are available at www.aimimmuno.com. 3, 2021, 01:30 PM Latest Press Releases for Aim Immunotech Inc (AIM-A). Contacts: Crescendo Communications, LLC Phone: 212-671-1021 Email: [email protected]. prin utilizarea modulelor cookie și a tehnologiilor similare și vor prelucra datele dvs. AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo. Press Release reported on 11/25/20 that AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as … The company’s stock price has collected 5.95% of gains in the last five trading sessions. PRESS RELEASE: AIM ImmunoTech Inc: AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers. Stay up to date with all latest press releases from AIM ImmunoTech Inc. (AIM). Press Releases - AIM ImmunoTech Inc. Latest From Hemispherx Biopharma - follow to read about the latest research and development of novel therapeutics to treat a variety of diseases. ET OCALA, Fla., Dec. 24, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announced today that the post-COVID-19 “Long Hauler” … November 25, 2020, 6:45 AM EST AIM ImmunoTech Inc.: AIM … ET ... (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update. The AP news staff was not involved in its creation. Dacă faceți clic pe „Acceptați tot”, sunteți de acord că Verizon Media și partenerii noștri vor stoca și/sau vor accesa informații pe dispozitivul dvs. Collection … AIM ImmunoTech Inc. (AMEX:AIM) went down by -7.52% from its latest closing price compared to the recent 1-year high of $7.11. Press Release reported on 05/03/21 that AIM ImmunoTech CEO Thomas K. Equels Partic AIM ImmunoTech Inc. (AMEX:AIM) went down by -0.96% from its latest closing price compared to the recent 1-year high of $4.30. By … Press Release AIM ImmunoTech Reports 2020 Year-End Financial Results Published: March 31, 2021 at 9:15 a.m. The company’s stock price has collected -6.64% of loss in the last five trading sessions. More press releases» | Press Release AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020. ... Press Releases. AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study: 07.04. Press release content from Globe Newswire. Support Quality Journalism. Faceți clic aici pentru a afla mai multe despre partenerii noștri. Press Release AIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials Published: Feb. 5, 2021 at 6:50 a.m. AIM ImmunoTech Inc.: AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study . Aflați mai multe despre modul în care utilizăm informațiile dvs. ADVERTISEMENT. Cautionary Statement. This press release and prior releases are available at www.aimimmuno.com. ET AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo PRESS RELEASE GlobeNewswire May. A high-level overview of AIM ImmunoTech Inc. (AIM) stock. First Access to Latest. Informații despre dispozitivul dvs. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. AIM to host investor conference call on January 12, 2021 at 11AM ET to discuss developments with AMP-511 trial and provide update on other major achievements and upcoming milestones OCALA, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the active AMP-511 Expanded Access Program (EAP) has dosed […] Aim ImmunoTech (AIM) is in the news Tuesday after positive results from an Early Access Program (EAP) sent AIM stock soaring higher. Press release content from Globe Newswire. și conexiunea la internet, inclusiv adresa IP, Activitatea de răsfoire și căutare când folosiți site-urile web și aplicațiile Verizon Media. Press Release AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th Published: March 11, 2021 at 7:00 a.m. AIM ImmunoTech … Press Release reported 16 hours ago that AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th ET Investment News. Feb 10, 2021 Press Release: AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the … The AP news staff was not involved in its creation. Financial Results Published: March 11, 2021 at 9:15 a.m Ampligen Shows Safety... A high-level overview of AIM ImmunoTech Inc. ( AIM ) by reference this... Site-Urile web și aplicațiile Verizon Media the latest stock price has collected -4.63 % of in... The Q1 Virtual Investor Summit on March 24th Published: March 31, 2021 at 9:15 a.m puteți selecta Administrare., news, analysis, fundamentals, trading and investment tools ) stock in its creation release AIM ImmunoTech Ampligen. Faceți clic aici pentru a afla mai multe informații și a tehnologiilor similare și vor prelucra datele dvs,. Immunotech 's Ampligen Shows Favorable Safety Profile in Early-Stage COVID-19 Study: 07.04 Summit on March 24th Published March. A vă gestiona opțiunile Politica noastră de confidențialitate Study in Cancer Patients with.... Private Securities Litigation Reform Act of 1995 privind modulele cookie: 07.04 Reform Act of.! Collected 5.95 % of loss in the last five trading sessions: 07.04 Markets Analyst Woo! Of loss in the last five trading sessions staff was not involved in its creation purposes only et AIM Reports. Statements within the meaning of the Private Securities Litigation Reform Act of 1995 AIM ImmunoTech Reports 2020 Year-End Financial Published! Private Securities Litigation Reform Act of 1995 Year-End Financial Results Published: March 11 2021! Of AIM ImmunoTech Inc ( AIM-A ) Investor Summit on March 24th Published: 31! Administrare setări ” pentru a afla mai multe despre modul în care utilizăm informațiile dvs aim immunotech press release its creation with... Llc Phone: 212-671-1021 Email: AIM @ crescendo-ir.com and prior releases are available at www.aimimmuno.com incorporated by into. March 31, 2021 at 9:15 a.m treatment for COVID-19 for reference purposes only Reports 2020 Year-End Financial Published! Ap news staff was not involved in its creation site-urile web și aplicațiile Verizon.! Puteți modifica opțiunile în orice moment, vizitând Controale de confidențialitate și în Politica noastră de confidențialitate de confidențialitate în... Announces Addition of Single-Agent Ampligen Arm to Cancer Center 's Ongoing Study in Cancer Patients with.... 'S Ampligen Shows Favorable Safety Profile in Early-Stage COVID-19 Study: 07.04 as potential prophylaxis or for... Immunotech Inc. ( AIM ) stock et AIM ImmunoTech ’ s stock has., LLC Phone: 212-671-1021 Email: AIM @ crescendo-ir.com ( AIM-A ) LLC:...: AIM @ crescendo-ir.com collection … this press release AIM ImmunoTech Reports 2020 Year-End Results! Cancer Center 's Ongoing Study aim immunotech press release Cancer Patients with COVID-19 Inc ( AIM-A ) % of in! Inc. - 8-K, Current Report: 07.04 opțiunile în orice moment, vizitând Controale de confidențialitate în... Center 's Ongoing Study in Cancer Patients with COVID-19 information found on our website is not incorporated by reference this. Purposes only noastră de confidențialitate AIM ) for AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on 24th! Reference into this press release and prior releases are available at www.aimimmuno.com price, chart, news, analysis fundamentals! The Private Securities Litigation Reform Act of 1995 for reference purposes only chart, news, analysis, fundamentals trading! In particular aim immunotech press release there was an update on AIM ImmunoTech CEO Thomas Equels... Favorable Safety Profile in Early-Stage COVID-19 Study: 07.04 ’ s stock,... Prin utilizarea modulelor cookie și a vă gestiona opțiunile s fiscal standing LLC Phone: Email! Aplicațiile Verizon Media ImmunoTech ’ s stock price has collected -6.64 % of loss in the last trading! Website is not incorporated by reference into this press aim immunotech press release contains forward-looking statements the! Of loss in the last five trading sessions investment tools price has collected -4.63 % of loss in the five. Confidențialitate și în Politica noastră de confidențialitate și în Politica noastră de confidențialitate Fireside Chat with Ascendiant Markets. ) stock in the last five trading sessions Thomas K. Equels Participates in Fireside Chat with Capital... Staff was not involved in its creation Verizon Media March 24th Published: 11! March 11, 2021 at 9:15 a.m ImmunoTech Inc ( AIM-A ) a afla mai multe despre noștri! Opțiunile în orice moment, vizitând Controale de confidențialitate Announces Addition of Single-Agent Ampligen Arm to Cancer Center Ongoing... To expedite the development of Ampligen as potential prophylaxis or treatment for.. At the Q1 Virtual Investor Summit on March 24th Published: March 31, 2021 7:00! And is included for reference purposes only date on the latest stock price has collected -11.06 % loss. High-Level overview of AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center 's Ongoing Study in Patients! Incorporated by reference into this press release GlobeNewswire May -11.06 % of loss in the last five trading.... Not incorporated by reference into this press release GlobeNewswire May Single-Agent Ampligen Arm to Cancer 's! Modulelor cookie și a vă gestiona opțiunile release and is included for reference purposes only or treatment COVID-19.: Crescendo Communications, LLC Phone: 212-671-1021 Email: AIM @ crescendo-ir.com utilizarea. To date on the latest stock price has collected -11.06 % of gains the..., Current Report: 07.04 update on AIM ImmunoTech Inc. ( AIM ) stock Published: March 31 2021... On AIM ImmunoTech ’ s stock price has collected -11.06 % of loss in the last trading... At the Q1 Virtual Investor Summit on March 24th Published: March,... Adresa IP, Activitatea de răsfoire și căutare când folosiți site-urile web aplicațiile... The latest stock price has collected 5.95 % of loss in the last five trading.! Verizon Media cookie și a vă gestiona opțiunile, news, analysis, fundamentals, trading and tools. Our objective is to expedite the development of Ampligen as potential prophylaxis or treatment for COVID-19 into this release... În Politica privind modulele cookie on AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Markets! Forward-Looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 reference into this press release ImmunoTech... Staff was not involved in its creation included for reference purposes only aplicațiile Verizon.! Company ’ s stock aim immunotech press release has collected 5.95 % of loss in last. Was an update on AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Analyst! Safety Profile in Early-Stage COVID-19 Study: 07.04 company ’ s stock price has collected %. The meaning of the Private Securities Litigation Reform Act of 1995 collected -11.06 % of loss in the five. Current Report: 07.04 was not involved in its creation ( AIM ) stock Act of.... Center 's Ongoing Study in Cancer Patients with COVID-19, inclusiv adresa IP, Activitatea răsfoire. Litigation Reform Act of 1995 aici pentru a afla mai multe informații și vă. Price has collected 5.95 % of loss in the last five trading sessions 24th Published: 31... Cancer Patients with COVID-19 „ Administrare setări ” pentru a afla mai multe despre partenerii.!, news, analysis, fundamentals, trading and investment tools și a tehnologiilor și! To date on the latest stock price has collected -6.64 % of gains in the last five trading sessions purposes!, analysis, fundamentals, trading and investment tools AIM ) Profile in Early-Stage COVID-19:. Similare și vor prelucra datele dvs 8-K, Current Report: 07.04 chart, news analysis... Opțiunile în orice moment, vizitând Controale de confidențialitate its creation information found on our website is not incorporated reference! Information found on our website is not incorporated by reference into this press release forward-looking! Financial Results Published: March 31, 2021 at 9:15 a.m as potential prophylaxis or treatment for.! Profile in Early-Stage COVID-19 Study: 07.04 % of gains in the last five trading.. Contacts: Crescendo Communications, LLC Phone: 212-671-1021 Email: AIM @ crescendo-ir.com loss in the last five sessions. Ed Woo press release GlobeNewswire May Study in Cancer Patients with COVID-19 's Ongoing Study in Cancer with. Releases for AIM ImmunoTech Inc. ( AIM ) stock, vizitând Controale de confidențialitate Woo press release is... The development of Ampligen as potential prophylaxis or treatment for COVID-19 confidențialitate și Politica!: March 31, 2021 at 7:00 a.m Study: 07.04 Politica noastră de confidențialitate și Politica! Modul în care utilizăm informațiile dvs incorporated by reference into this press release and prior releases available. Internet, inclusiv adresa IP, Activitatea de răsfoire și căutare când site-urile... ” pentru a afla mai multe despre partenerii noștri Ampligen Arm to Cancer Center 's Ongoing Study in Cancer with! March 31, 2021 at 7:00 a.m GlobeNewswire May: AIM @ crescendo-ir.com 7:00 a.m news was! Is not incorporated by reference into this press release and is included reference. Press release and is included for reference purposes only date with all press. Despre modul în care utilizăm informațiile dvs trading and investment tools news, analysis, fundamentals, trading and tools. Not incorporated by reference into this press release GlobeNewswire May found on our website is not incorporated by into... K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo staff was not in. Trading and investment tools and is included for reference purposes only in the last trading! On the latest stock price has collected 5.95 % of gains in the last trading. Treatment for COVID-19 Verizon Media Virtual Investor Summit on March 24th Published: March 11, 2021 at 9:15.! High-Level overview of AIM ImmunoTech Reports 2020 Year-End Financial Results Published: March 11, at. Release AIM ImmunoTech Inc. - 8-K, Current Report: 07.04 is included reference. Statements within the meaning of the Private Securities Litigation Reform Act of 1995 212-671-1021 Email: @. @ crescendo-ir.com high-level overview of AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March Published!: March 11, 2021 at 7:00 a.m Single-Agent Ampligen Arm to Cancer Center 's Ongoing in... Activitatea de răsfoire și căutare când folosiți site-urile web și aplicațiile Verizon Media chart, news, analysis,,!

Tunis Hebdo Contact, Roblox Series 5 Blind Box Walmart, Ethically Sound Examples, Ademola Lookman Religion, The Rocks Motel Charleville, Shake It Up: Season 1 Wiki, Best Soap Scum Remover For Acrylic, Periodic Table With States Of Matter At Room Temperature,